Trial
NCT05584202
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
ModernaTX, Inc.
Collaborators
—
Condition
SARS-CoV-2
Intervention
mRNA-1273.214
Why stopped
The trial was terminated because data from the dose finding part of the trial did not support further evaluation of effectiveness of mRNA-1273. There were no safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-26